Zomedica Pharmaceuticals Corp. (NYSE:ZOM) traded at $0.24 at last check on Tuesday, Jun 30, making a downturn move of -7.18% on its previous day’s price.
Looking at the stock we see that its previous close was $0.262 and the beta (5Y monthly) reads 0.04 with the day’s price range being $0.2370 – 0.2509. In terms of its 52-week price range, ZOM has a high of $0.499 and a low of $0.11. The company’s stock has gained about 66.14% over that past 30 days.
On the other hand, looking at the outlook for the ZOM stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of Hold.
Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Zomedica Pharmaceuticals Corp. (ZOM) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Let’s briefly compare Zomedica (ZOM) stock to its peers. We find that today’s price change of -7.18% and +13.86% over the past 12 months for ZOM competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price rise 2% in the latest trading session and is +16.29% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has dropped -1.91% today, and is +2.32% up over the past year, while Grifols S.A. (GRFS) is also down -7.18% yet its price remains in the green at 13.86% over the same period. Zoetis has a P/E ratio of 39.26 compared to Zomedica’s 0 and Takeda’s 22.32. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.04% and 0.46%, respectively, in early deals.
Coming back to Zomedica Pharmaceuticals Corp. (NYSE:ZOM), we note that the average 3-month trading volume was 46.81 Million, while that of the preceding 10-day period stands at 122.72 Million. Current shares outstanding are 313.46 Million.
According to data from Thomson Reuters, insiders hold 38.45% of the company’s shares while institutions hold 9.67%. The data shows that short shares as of June 14, 2020, stood at 7.15 Million at a short ratio of 0.15. This represents a 2.45% Short interest in Shares outstanding on June 14, 2020. Shares short dropped in June from the previous month at 10.42 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -20.85% down in year-to-date price movement.